CAMBRIDGE, Mass. (August 19, 2016) – Platelet BioGenesis, a biotech startup developing a method for producing life-saving platelets without the need for human donations, is excited to announce that Dr. Philip Reilly and Mr. William (Bill) Nyhan have joined the company’s Board of Directors.
Philip Reilly, MD, JD brings expansive experience in stem cell therapeutics, patient care, and launching and building biotech companies. Phil has spent the past eight years as a Venture Partner at Third Rock Ventures and played integral roles in founding several companies including Edimer, Bluebird Bio, Lotus Tissue Repair, Voyager Therapeutics, and Fulcrum Therapeutics. Phil is a trustee emeritus of Cornell University, an Overseer of Weill Cornell Medical College, and serves on the Advisory Board to the Boston University School of Public Health.
Bill Nyhan has deep experience in finance, investing in early stage companies, and growing businesses across a variety of different industries. Bill has co-founded numerous companies, most recently Environments at Work where he currently serves as COO and CFO. He also currently sits on the boards of: Aras Corporation, Environments at Work, Libboo Corporation, and MediaMate. Bill co-founded eCoast Angels (investors in Platelet BioGenesis) and previously served as a General Partner of Aconcagua Company, a venture capital firm. Bill’s additional experience includes founder of Atlas Water Leasing, a Principal and Vice President of York Hill Company, a lecturer at the Boston College Graduate School of Management, and as a member of the US Coast Guard’s Search and Rescue Unit.
“As Platelet BioGenesis continues to grow and progress towards clinical trials, we are confident Phil and Bill will bring a greater depth and breadth of experience to the team,” said Sven Karlsson, President of Platelet BioGenesis. “In working to create a source of platelets with no risk of bacterial or viral contamination, the team shares my passion for improving patient care,” Phil comments, “delivering this superior care at a lower cost offers a profound opportunity to reshape the platelet market”. Bill added, “as we previously saw with HIV and Hep C, and we are currently experiencing with the spread of Zika, freeing our blood supply from human donors and the inherent associated risk of viral contamination is imperative.”
“Platelet BioGenesis has proven our ability to produce platelets directly from stem cells, Phil and Bill will help us realize our vision to change the world by commercializing this technology,” said Dr. Jonathan Thon, Assistant Professor at Brigham and Women’s Hospital and inventor of Platelet BioGenesis’ patented bioreactor.
Philip Reilly and Bill Nyhan join board members Joseph Italiano, Associate Professor at Harvard Medical School, Jonathan Thon, Assistant Professor at Brigham and Women’s Hospital, and Sven Karlsson. About Platelet BioGenesis (www.plateletbiogenesis.com; twitter @plateletbiogen) Platelet BioGenesis is a pre-clinical stage biotech company that was spun out of Harvard in 2014 to produce donor-independent human platelets from pluripotent stem cells Platelet BioGenesis has developed and patented a microfluidic bioreactor, and shown that functional platelets can be generated from human stem cell cultures at scale. The company was selected to participate in MassCONNECT (run by MassBio), was a 2014 MassChallenge Finalist, a 2016 BioSciKin business competition winner, and has received support from the Massachusetts Life Sciences Center, and the NIH.
Platelet BioGenesis Whitney Berry | (720) 509.9448